Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Mar 5 2014

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.

"We are encouraged that the safety and pharmacokinetic profile observed in Japanese patients in this Phase 1 study is consistent with that seen in the US Phase 1 study," said Dr. Joanna Horobin, Verastem Chief Medical Officer. "With these data in hand, we are speaking with the Japanese regulatory authorities about the potential for opening COMMAND trial sites in Japan later this year."

Verastem's ongoing COMMAND trial is a randomized, double-blind, placebo controlled registration-directed study which is evaluating VS-6063 in patients with mesothelioma and is currently accruing patients in 8 countries.

The Japanese Phase 1 is an open-label, dose-escalation study that enrolled nine subjects who received single-agent VS-6063 (200, 400 or 600mg; n=3 in each dose cohort) BID. The study results demonstrated that VS-6063 was well tolerated at all dose levels. There were no serious adverse events or evidence of dose-limiting toxicity. Pharmacokinetic results from the recommended Phase 2 dose of 400mg BID were consistent with previously reported data in non-Japanese subjects. These safety and pharmacokinetic results support advancing the VS-6063 development program in Japanese patients.

"We have now completed full enrollment and VS-6063 was well tolerated at each dose level," said Toshio Shimizu, M.D., Ph.D., Assistant Professor, Phase 1 Clinical Trials Program, Department of Medical Oncology, Kinki University Faculty of Medicine and Principal Investigator of the study. "The study was open to patients with all solid tumors and one of the patients has mesothelioma. This patient is enrolled in the 400mg BID dose cohort and is responding well to treatment, continues on trial and is currently in cycle 7 of treatment. At this point their disease remains stable and we have seen an improvement in clinical symptoms. These data are encouraging and we hope to continue development of VS-6063 in Japan in parallel with the United States and Europe."

SOURCE Verastem, Inc.